Soft tissue sarcomas associated with neurofibromatosis: treatment experience

Author:

Zubarev A. L.1ORCID,Kurilchik A. A.1ORCID,Ivanov V. E.1ORCID,Starodubtsev A. L.1ORCID,Khanina2 M. K.2ORCID

Affiliation:

1. A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

2. Obninsk Institute for Nuclear Power Engineering – branch of National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)

Abstract

Soft tissue sarcomas are a rare and heterogeneous group of solid tumors originating from the mesenchyme and accounting for only 1 % of all malignant neoplasms in adults. The modern clinical and morphological World Health Organization of soft tissue sarcomas classification includes more than 100 forms of these tumors. Neurofibromatosis is a group of hereditary, autosomal dominant diseases characterized by the development of multiple tumor formations, often benign. Currently, there are 3 types: neutrophibromatosis type I, neurofibromatosis type II and schwannomatosis. The estimated risk of developing sarcoma in patients with neurofibromatosis type 1 at age 30 years is 25.1 %, and by age 50 years it is 38.8 %. Treatment of soft tissue sarcomas associated with neurofibromatosis fully complies with the standard recommendations of National Comprehensive Cancer Network, NCCN (NCCN), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and RUSSCO and does not have its own peculiarities. Over the past 15 years, at the A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, more than 190 patients with locally advanced, high-grade soft tissue sarcomas have been treated, including five patients with sarcomas associated with neurofibromatosis. The article presents clinical cases of treatment of soft tissue sarcomas associated with neurofibromatosis.

Publisher

Publishing House ABV Press

Reference22 articles.

1. Von Mehren M., Kane J.M., Agulnik M. et al. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma Version 1.2024. April 26, 2024. Available at: https://escholarship.org/uc/item/5pc8g7x1.

2. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7–33. DOI: 10.3322/caac.21708

3. Kempson R.L., Fletcher C.D., Evans H.L. et al.Tumors of the soft tissues. Atlas of tumor pathology. 3rd series. Bethesda, Maryland, 2001. Pp. 1–420.

4. Pisters P.W.T., Weiss M., Maki R. Soft-tissue sarcomas. In: Cancer management: a multidisciplinary approach medical, surgical, & radiation oncology. 14th edn. Ed. by D.G. Haller, L.D. Wagman, C. Camphausen, W.J. Hoskins/UBM Medica LLC; 2011.

5. Makashova E.S., Karandasheva K.O., Zolotova S.V. et al. Neurofibromatosis: analysis of clinical cases and new diagnostic criteria. Nervno-myshechnye bolezni = Neuromuscular Diseases 2022;12(1):39–48. (In Russ.).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3